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To the Editor, 30 
Mepolizumab is a humanised interleukin 5 (IL-5) antagonist monoclonal antibody used for the 31 
treatment of uncontrolled severe eosinophilic asthma (SEA). Increased IL-5 expression and local 32 
eosinophilic inflammation have a key role in the pathogenesis of SEA and chronic rhinosinusitis and 33 
nasal polyps (CRSwNP).1 Targeting IL-5 with mepolizumab (MEPO) which is a central protagonist of 34 
eosinophilic type 2 inflammation (T2) has achieved good results in reducing asthma exacerbations. 2, 3 35 
Here we present a series of six retrospective cases of never smokers with uncontrolled SEA and 36 
concomitant CRSwNP, in relation to their disconnected response to MEPO at the standard 37 
subcutaneous dose of 100mg every four weeks (q4w) which was administered under supervision. In 38 
this case series, MEPO was commenced for the treatment of SEA as it does not yet have a license for 39 
CRSwNP. Patient demographics are summarised in the table. All patients had negative MPO or PR3 40 
antibodies and negative Aspergillus fumigatus IgE and IgG antibodies. Asthma control questionnaire 41 
(ACQ-6), spirometry, CT sinuses, nasal endoscopy (30 degree oblique rigid Hopkins 3.0mm endoscope) 42 
and blood eosinophil count are all routinely performed in our regional rhinology mega-clinic. 43 
CRSwNP burden was initially assessed endoscopically according to Lildholdt scoring with all 44 
endoscopies being performed by at least one of the authors.4 Lildholt et al graded severity of nasal 45 
polyps using a 0 - 3 point system for each nostril i.e. total score out of 6. A score of 1 implies mild 46 
polyposis i.e. small polyps not reaching the upper edge of the inferior turbinate. A score of 2 suggests 47 
moderate polyposis where medium sized polyps reach between the upper and lower edge of the 48 
inferior turbinate. Finally, a score of 3 advocates severe polyposis i.e. large polyps reaching below the 49 
lower edge of the inferior turbinate. A patient with severe bilateral nasal polyposis would therefore 50 
have a maximum score of 6. CRSwNP burden was subsequently assessed radiologically using CT Lund-51 
Mackay scoring (out of 24).  52 
In one study 38/54 (70%) patients did not respond to iv MEPO 750mg, with response measured as a 53 
reduced need for nasal polyp surgery.5 In the second study, 8/20 (40%) did not respond to iv MEPO 54 
750mg, with response described as a reduction in total polyp score.6 In this case series, the mean 55 
duration of MEPO treatment was 9 months. We observed a significant improvement in asthma control 56 
from a mean ACQ-6 of 3.4 before versus 0.3 after MEPO. An ACQ score of less than 0.75 denotes good 57 
control and more than 1.5 denotes poor control. Moreover ACQ score is a strong predictor of future 58 
exacerbation risk.7 The mean number of asthma exacerbations requiring oral corticosteroids (OCS) in 59 
the ensuing 12 months fell from 4 before treatment to 1 after treatment. Blood eosinophils fell in all 60 
cases as expected with anti-IL5 treatment from a mean of 1393 to 120 cells/ul.  61 
However, the improvements in asthma control were not mirrored by CRSwNP. Mean endoscopic NP 62 
score pre-treatment was 5 and remained unchanged after treatment (table). The mean number of 63 
CRSwNP exacerbations requiring OCS in the 12 months was also unchanged pre and post treatment. 64 
Furthermore, all patients had persistent anosmia pre and post MEPO. Pointedly, these observations 65 
were noted in a patient cohort with a high nasal polyp burden reflected by a mean Lund-Mackay score 66 
of 21/24 in addition to a high blood eosinophil count, thus representing a group who would be 67 
expected to receive benefit from MEPO.  68 
Our indication for OCS for a CRSwNP exacerbation would be worsening blockage and anosmia 69 
together with increased often purulent secretions. Patients are normally referred from primary or 70 
secondary care to our specialist rhinology mega-clinic where we are supported by specialist ENT 71 
nurses and have access to point-of-care nasal endoscopy. Our patients with severe disease following 72 
several oral steroid pulses are also usually offered the option of seeing an ENT surgeon (in the same 73 
clinic) to discuss the merits and risks of surgery. Inevitably most patients opt for medical polypectomy 74 
with our standard Tayside polyp-clear regimen of 2 weeks of oral prednisolone 25mg daily and 3 days 75 
of azithromycin 500mg daily and fluticasone nasules 400µg twice daily. 76 
Patient 2 was the only one with evidence of airway obstruction in terms of low FEV1 %. It is well 77 
recognised frequent exacerbations in conjunction with preserved lung function may occur in patients 78 
with SEA. Patient 6 had previously been commenced on omalizumab therapy for severe atopic asthma 79 
but was subsequently switched to mepolizumab as their control worsened requiring frequent courses 80 
of OCS.  81 
Our clinical experience with MEPO for SEA with concomitant CRSwNP therefore differs from the 82 
results achieved from previous studies.5, 6 Our patients responded favourably to MEPO in terms of 83 
asthma control, but their CRSwNP disease persisted and, in some cases, continued to worsen. To 84 
further elucidate this point, patient 4 underwent functional endoscopic sinus surgery (FESS) alongside 85 
MEPO for asthma but experienced NP recurrence within four months. Similarly, patient 1 underwent 86 
FESS prior to commencing MEPO but still experienced worsening endoscopic and clinical outcomes 87 
having had clear ethmoid and sphenoid cavities in the immediate postoperative period. It is also worth 88 
pointing out that while patients 1 and 2 experienced no exacerbations of CRSwNP requiring OCS per 89 
se they still had a high Lund Mackay score. 90 
This observed disconnect in MEPO response between upper and lower airways could perhaps be 91 
explained by an insufficient dose of MEPO resulting in lack of efficacy for the treatment of eosinophilic 92 
CRSwNP. Two randomised controlled trials (RCT) demonstrated that intravenous MEPO 750mg q4w 93 
reduced NP size or the need for FESS, but the dose was much higher than the standard subcutaneous 94 
100mg q4w dose used here. 5, 6 There is an ongoing RCT looking at MEPO in CRSwNP using the standard 95 
100mg subcutaneous dose (NCT03085797). Interestingly Laidlaw et al recently reported on a 96 
disconnect between depletion of blood and tissue eosinophils with Dexpramipexole over 6 months 97 
with no change in polyp size or improvement in symptoms.8 Two phase 3 studies with dupilumab, an 98 
IL-4 receptor alpha monoclonal antibody in CRSwNP as add on therapy to nasal corticosteroid spray 99 
showed that it significantly improves endoscopic, radiological, clinical, patient-reported sino-nasal and 100 
asthma outcomes, despite there being no reduction in blood eosinophils, but no polyp biospies were 101 
reported.9  102 
We appreciate there are limitations to interpreting our study. First, we did not perform CT scans after 103 
MEPO as this is not part of our routine clinic follow-up protocol to avoid unnecessary ionising 104 
radiation. Second, we did not record formal symptom scores such as SNOT-22 or objective smell 105 
testing because this is not usually performed in our NHS clinic. However, none of our patients 106 
spontaneously reported any recovery in their sense of smell. Nonetheless it can be seen that our 107 
patients overall had an appreciable NP burden based on their endoscopy and CT scores. Finally we 108 
would like to emphasise that this was a real world retrospective case series based on case note review 109 
and as such may not reflect results from prospective RCTs or prospective real life follow up trials.    110 
In conclusion standard doses of MEPO significantly improved asthma control but not NP in our 111 
cohort of uncontrolled SEA patients with concomitant CRSwNP. 112 
 113 
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Table – patient demographics and clinical parameters pre and post mepolizumab 146 
Patient 1 2 3 4 5 6 
Age 49 37 53 61 58 65 
Gender F F M F F M 
AERD + + - + - - 



















Total IgE kU/L 94 60 423 270 94 420 
Pre MEPO  
ACQ-6 2.3 3.9 3.6 5.5 3 2.3 
Eos cells/uL 1540 1330 1380 1520 1760 830 
FEV1 %   92 63 109 118 96 81 
Asthma exac#  4 4 4 4 6 4 
CRSwNP exac# 0 0 2 2 2 1 
LM score 23 21 23 19 24 14 
NP score 0* 5 6 6 6 5 
Post MEPO 
ACQ6 0 0.3 1 0 0 0.7 
Eos cells/uL 90 90 340 90 80 30 
FEV1 %  93 77 101 107 96 70 
Asthma exac# 0 0 1 1 0 2 
CRSwNP exac# 0 0 2 2 1 2 
NP score 2 5 6 6 6 6 
ACQ = asthma control questionnaire, AERD = aspirin-exacerbated respiratory disease, AZEL = azelastine nasal 
spray, AZI = azithromycin, BUD = budesonide, CET = cetirizine, CROMO = sodium cromoglicate, CRSwNP = chronic 
rhinosinusitis with nasal polyps, Eos = eosinophils, exac = exacerbations, FEV1 = forced expiratory volume in 1 
second, FM = formoterol, FPN = fluticasone proprionate nasal spray, FF = fluticasone furoate, IgE = 
Immunoglobulin E, LM = Lund Mackay score, MEPO = mepolizumab, ML = montelukast, NP = nasal polyp, TIO = 
tiotropium, UMEC = umeclidinium, VIL = vilanterol, # denotes number of asthma or CRSwNP exacerbations 
requiring oral corticosteroids in the preceding 12 months, * patient underwent surgical polypectomy prior to 
MEPO 
 147 
